Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) have received a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $5.6667.

IPHA has been the subject of several recent research reports. UBS Group reissued a “buy” rating on shares of Innate Pharma in a research note on Tuesday. HC Wainwright lifted their target price on shares of Innate Pharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday. Weiss Ratings raised shares of Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 26th. Finally, Citigroup upgraded shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research report on Tuesday.

Institutional Trading of Innate Pharma

Institutional investors have recently bought and sold shares of the company. OLD Mission Capital LLC bought a new position in Innate Pharma in the 4th quarter valued at approximately $50,000. Millennium Management LLC purchased a new stake in Innate Pharma during the fourth quarter valued at $36,000. Finally, Jane Street Group LLC purchased a new stake in shares of Innate Pharma during the 4th quarter valued at about $162,000. 0.16% of the stock is owned by hedge funds and other institutional investors.

Innate Pharma Stock Up 28.3%

Shares of IPHA opened at $2.22 on Tuesday. Innate Pharma has a 1 year low of $1.17 and a 1 year high of $2.62. The stock has a 50 day simple moving average of $1.80 and a two-hundred day simple moving average of $1.67.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.